Initial public offerings scheduled to debut next week

The Associated Press 0

NEW YORK, N.Y. – The following is a list of initial public offerings planned for the coming week. Sources include Renaissance Capital, Greenwich, CT (www.renaissancecapital.com) and SEC filings.

Week of February 3

Argos Therapeutics Inc. – Durham, N.C., 4.3 million shares, priced $13 to $15, managed by Piper Jaffray, Stifel, and JMP Securities. Proposed Nasdaq symbol ARGS. Business: Developing immunotherapies for the treatment of cancer and HIV. Previously filed and withdrew in 2012.

Auspex Pharmaceuticals Inc. – San Diego, 5.5 million shares, priced $10 to $12, managed by Stifel and BMO Capital Markets. Proposed Nasdaq symbol ASPX. Business: Clinical-stage biotech developing treatments for orphan diseases.

Biocept Inc. – San Diego, 1.8 million shares, priced $10 to $12, managed by Aegis Capital. Proposed Nasdaq symbol BIOC. Business: Develops and markets cancer diagnostic tests.

Continental Building Products Inc. – Reston, Va., 13.2 million shares, priced $16 to $18, managed by Citigroup, Credit Suisse, and Barclays. Proposed NYSE symbol CBPX. Business: Manufactures and sells drywall in the eastern U.S. and Canada.

Egalet Corp. – Malvern, Pa., 3.5 million shares, priced $11 to $13, managed by Stifel and JMP Securities. Proposed Nasdaq symbol EGLT. Business: Developing abuse-deterrent oral products for the treatment of pain.

Eleven Biotherapeutics Inc. – Cambridge, Mass., 4.3 million shares, priced $13 to 415, managed by Citigroup, Cowen & Co., and Leerink Partners. Proposed Nasdaq symbol EBIO. Business: Clinical-stage biotech developing protein therapeutics to treat eye diseases.

Genocea Bioscience Inc. – Cambridge, Mass., 5.5 million shares, priced $12 to $14, managed by Citigroup and Cowen & Co. Proposed Nasdaq symbol GNCA. Business: Develops novel vaccines for infectious diseases through T cell immune responses.

GeoPark Ltd. – Santiago, Chile, 20 million shares, priced $8 to $10, managed by J.P. Morgan, BTG Pactual, and Itau BBA. Proposed NYSE symbol GPRK. Business: Oil and natural gas exploration and production company operating in Chile, Colombia, and Brazil. Trades in Santiago and London.

Ladder Capital Corp. – New York, 13.3 million shares, priced $16 to $18, managed by Deutsche Bank, Citigroup, and Wells Fargo. Proposed NYSE symbol LADR. Business: Commercial real estate mortgage origination and finance company.

NephroGenex Inc. – Research Triangle Park, N.C., 3.1 million shares, priced $12 to $14, managed by Aegis Capital. Proposed Nasdaq symbol NRX. Business: Clinical-stage biotech developing treatments for kidney disease.

Revance Therapeutics Inc. – Newark, Calif., 5 million shares, priced $14 to $16, managed by Cowen & Co., and Piper Jaffray. Proposed Nasdaq symbol RVNC. Business: Clinical-stage biotech developing enhanced formulations of botulinum toxin (Botox).

UniQure N.V. – Amsterdam, Netherlands, 4.6 million ordinary shares, priced $13 to $15, managed by Jefferies, Leerink Partners, and Piper Jaffray. Proposed Nasdaq symbol QURE. Business: Develops gene therapies for the treatment of orphan diseases.

Leave a comment

Your email address will not be published. Required fields are marked *